Back to nephrectomy for patients with metastatic renal cancer.
Klotz
L
L
Department of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario M4N 3M5, Toronto, Canada. Laurence.Klotz@swchsc.on.ca
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D009392:Nephrectomy; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D016019:Survival Analysis
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins